Dashboard
Manage Tickers

VYNEVYNE Therapeutics Inc.

Nasdaq vynetherapeutics.com


$ 1.91 $ 0.12 (6.74 %)    

Tuesday, 10-Sep-2024 15:53:40 EDT
CLICK TO SEE RELEVANT LITIGATION UPDATES
Y-mAbs Therapeutics, Inc. | YMAB | Take Action!
QQQ $ 458.06 $ 4.20 (0.92 %)
DIA $ 408.23 $ -0.79 (-0.19 %)
SPY $ 548.63 $ 2.38 (0.44 %)
TLT $ 100.67 $ 0.70 (0.7 %)
GLD $ 232.64 $ 1.02 (0.44 %)
$ 1.9
$ 1.77
$ 1.85 x 300
-- x --
$ 1.77 - $ 1.91
$ 1.57 - $ 4.48
29,507
na
28.02M
$ 0.92
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 08-14-2024 06-30-2024 10-Q
2 05-09-2024 03-31-2024 10-Q
3 03-01-2024 12-31-2023 10-K
4 11-13-2023 09-30-2023 10-Q
5 08-14-2023 06-30-2023 10-Q
6 05-11-2023 03-31-2023 10-Q
7 03-14-2023 12-31-2022 10-K
8 11-14-2022 09-30-2022 10-Q
9 08-12-2022 06-30-2022 10-Q
10 05-12-2022 03-31-2022 10-Q
11 03-17-2022 12-31-2021 10-K
12 11-10-2021 09-30-2021 10-Q
13 08-12-2021 06-30-2021 10-Q
14 05-06-2021 03-31-2021 10-Q
15 03-04-2021 12-31-2020 10-K
16 11-05-2020 09-30-2020 10-Q
17 08-06-2020 06-30-2020 10-Q
18 05-11-2020 03-31-2020 10-Q
19 03-03-2020 12-31-2019 10-K
20 10-31-2019 09-30-2019 10-Q
21 08-01-2019 06-30-2019 10-Q
22 05-02-2019 03-31-2019 10-Q
23 02-28-2019 12-31-2018 10-K
24 11-07-2018 09-30-2018 10-Q
25 08-01-2018 06-30-2018 10-Q
26 05-09-2018 03-31-2018 10-Q
27 03-28-2018 12-31-2017 10-K
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

hc-wainwright--co-reiterates-buy-on-vyne-therapeutics-maintains-575-price-target
HC Wainwright & Co. Reiterates Buy on VYNE...
08/15/2024 09:57:30

HC Wainwright & Co. analyst Joseph Pantginis reiterates VYNE Therapeutics (NASDAQ:VYNE) with a Buy and maintains $5.75 p...

vyne-therapeutics-q2-2024-gaap-eps-022-misses-019-estimate-sales-198000k-beat-110000k-estimate
VYNE Therapeutics Q2 2024 GAAP EPS $(0.22)...
08/14/2024 12:07:27

VYNE Therapeutics (NASDAQ:VYNE) reported quarterly losses of $(0.22) per share which missed the analyst consensus estimate of $...

vyne-therapeutics-announces-composition-of-matter-patent-for-its-vyn202-bd2-selective-bet-inhibitor
VYNE Therapeutics Announces Composition Of...
07/16/2024 12:05:42

12-health-care-stocks-moving-in-thursdays-intraday-session
12 Health Care Stocks Moving In Thursday's...
06/20/2024 16:32:10

analyst-scoreboard-4-ratings-for-vyne-therapeutics
Analyst Scoreboard: 4 Ratings For VYNE The...
06/14/2024 13:01:32

hc-wainwright--co-reiterates-buy-on-vyne-therapeutics-maintains-575-price-target
HC Wainwright & Co. Reiterates Buy on VYNE...
06/14/2024 10:01:57

HC Wainwright & Co. analyst Joseph Pantginis reiterates VYNE Therapeutics (NASDAQ:VYNE) with a Buy and maintains $5.75 p...

vyne-therapeutics-doses-first-volunteers-in-phase-1a-trial-of-vyn202-oral-bet-inhibitor-targeting-immuno-inflammatory-diseases-top-line-data-expected-in-h2-2024
VYNE Therapeutics Doses First Volunteers I...
06/13/2024 13:04:50

hc-wainwright--co-reiterates-buy-on-vyne-therapeutics-maintains-575-price-target
HC Wainwright & Co. Reiterates Buy on VYNE...
06/05/2024 15:21:26

HC Wainwright & Co. analyst Joseph Pantginis reiterates VYNE Therapeutics (NASDAQ:VYNE) with a Buy and maintains $5.75 p...

vyne-therapeutics-doses-first-subject-in-phase-2b-vitiligo-trial-of-vyn201
VYNE Therapeutics Doses First Subject In P...
06/05/2024 12:01:46

hc-wainwright--co-reiterates-buy-on-vyne-therapeutics-maintains-575-price-target
HC Wainwright & Co. Reiterates Buy on VYNE...
05/09/2024 15:27:59

HC Wainwright & Co. analyst Joseph Pantginis reiterates VYNE Therapeutics (NASDAQ:VYNE) with a Buy and maintains $5.75 p...

vyne-therapeutics-q1-eps-015-beats-024-estimate-sales-9800k-miss-10000k-estimate
VYNE Therapeutics Q1 EPS $(0.15) Beats $(0...
05/09/2024 13:06:19

VYNE Therapeutics (NASDAQ:VYNE) reported quarterly losses of $(0.15) per share which beat the analyst consensus estimate of $(0...

hc-wainwright--co-reiterates-buy-on-vyne-therapeutics-maintains-575-price-target
HC Wainwright & Co. Reiterates Buy on VYNE...
05/06/2024 14:45:06

HC Wainwright & Co. analyst Joseph Pantginis reiterates VYNE Therapeutics (NASDAQ:VYNE) with a Buy and maintains $5.75 p...

12-health-care-stocks-moving-in-mondays-pre-market-session
12 Health Care Stocks Moving In Monday's P...
05/06/2024 12:06:38

vyne-therapeutics-announces-fda-clearance-of-ind-application-for-vyn202
VYNE Therapeutics Announces FDA Clearance ...
05/06/2024 12:04:29

vyne-therapeutics-presents-vyn201-at-2024-sid-annual-meeting
VYNE Therapeutics Presents VYN201 At 2024 ...
05/01/2024 12:45:19

Presentations will highlight positive preclinical and Phase 1b data of novel BET inhibitor, VYN201, in nonsegmental vitiligo

12-health-care-stocks-moving-in-fridays-after-market-session
12 Health Care Stocks Moving In Friday's A...
03/29/2024 20:30:47

hc-wainwright--co-reiterates-buy-on-vyne-therapeutics-maintains-575-price-target
HC Wainwright & Co. Reiterates Buy on VYNE...
02/29/2024 20:06:04

HC Wainwright & Co. analyst Joseph Pantginis reiterates VYNE Therapeutics (NASDAQ:VYNE) with a Buy and maintains $5.75 p...

recap-vyne-therapeutics-q4-earnings
Recap: VYNE Therapeutics Q4 Earnings
02/29/2024 13:30:06

vyne-therapeutics-ended-2023-with-933m-of-cash-cash-equivalents-restricted-cash-and-marketable-securities-providing-runway-through-the-end-of-2025
VYNE Therapeutics Ended 2023 With $93.3M O...
02/29/2024 13:12:41

vyne-therapeutics-q4-adjusted-eps-018-beats-050-estimate-sales-7600k-miss-15000k-estimate
VYNE Therapeutics Q4 Adjusted EPS $(0.18) ...
02/29/2024 13:12:15

VYNE Therapeutics (NASDAQ:VYNE) reported quarterly losses of $(0.18) per share which beat the analyst consensus estimate of $(0...

CORE & Plaid

CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION